MarksMan Healthcare combines scientific expertise with proprietary AI-enabled platforms to support patient and clinician insights, evidence planning, medical affairs, market access and biopharma partnering. Our platforms strengthen expert-led engagements through tailored workflows, human review and source traceability.
Explore our platforms below, or speak with us about the evidence and business questions your team needs to address.
Bring patient priorities into evidence planning.
Connects patient perspectives with patient-reported outcomes, published real-world evidence and regulatory and HTA evidence. Helps identify unmet needs, treatment burdens and priorities across the patient journey to inform research questions, advisory discussions and evidence-generation plans.
Explore Platform (opens in a new tab)Understand clinician perspectives in scientific context.
Synthesises healthcare professional perspectives from congress materials, published expert discussions and educational sources alongside scientific evidence. Helps identify treatment preferences, areas of consensus or disagreement and barriers to adoption to inform medical strategy and research priorities.
Explore Platform (opens in a new tab)Prepare for EU Joint Clinical Assessment.
Supports Joint Clinical Assessment readiness through PICO-based evidence mapping and gap assessment. Helps teams anticipate questions around populations, comparators and outcomes, and translate them into evidence-generation priorities as the evidence and assessment landscape evolve.
Explore Platform (opens in a new tab)Connect global evidence with local access needs.
Supports market-access readiness and prioritisation across geographies. Helps teams assess where existing evidence can be reused and where additional local evidence may be needed, informing market selection, launch sequencing and evidence-generation investment.
Explore Platform (opens in a new tab)Translate field insights into medical priorities.
Organises insights from MSL–KOL interactions and medical engagements into structured scientific themes. Helps identify recurring evidence gaps, treatment challenges and emerging questions to inform advisory boards, real-world evidence studies, publication planning and scientific follow-up.
Explore Platform (opens in a new tab)Connect assets with relevant partnering opportunities.
Supports in-licensing and out-licensing through AI-enabled asset mapping and partner identification. Helps pharmaceutical and biotechnology companies identify assets aligned with strategic priorities, assess potential partners and progress targeted introductions and partnering discussions.
Explore Platform (opens in a new tab)Our platforms support the identification of evidence needs and strategic priorities. MarksMan's teams can take these forward through evidence synthesis, real-world evidence, HEOR, biostatistics, market-access support and scientific communications, with the scope tailored to each engagement.
Tell us about your objectives. We can help identify the relevant platform, scientific expertise and scope of support for your team.